Immatics N.V. (IMTX)Healthcare | Biotechnology | Tübingen, Germany | NasdaqCM
7.17 USD
+0.17
(2.429%)
⇧
(Oct. 15, 2026, 3:56 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 11:18 a.m. EDT
The long-term outlook remains fundamentally compromised by persistent losses and negative operating cash flow, which are typical for biotech firms but currently outweighed by the severe multi-year price decline. Although the company recently posted a positive year-over-year gain, the stock has lost nearly half its value over the last six years, signaling that the market views the current business model as struggling to generate sustainable value. This structural deterioration caps the long-term rating despite the recent uptick in performance. In the short term, the technical picture is grim. The stock is trading well below its 50-day and 200-day moving averages, confirming a downtrend that has persisted for months. While the recent price action shows a slight bounce, the heavy concentration of put options suggests that traders are actively hedging against further drops rather than betting on a reversal. The statistical forecast offers no directional guidance, reinforcing the view that the immediate path is uncertain and likely to remain under pressure until the company can demonstrate a clearer path to profitability or a major catalyst. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.086195 |
| AutoETS | 0.096745 |
| AutoARIMA | 0.096749 |
| AutoTheta | 0.101161 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 10.77 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.039 |
| Excess Kurtosis | 0.30 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 3.655 |
| Revenue per Share | 0.322 |
| Market Cap | 1,091,453,824 |
| Forward P/E | -3.54 |
| Beta | 1.36 |
| Website | https://www.immatics.com |
As of Oct. 10, 2026, 11:18 a.m. EDT: Speculators are heavily positioned for downside protection, with significant put volume and open interest concentrated in the near term (October/November 2026) at strikes just above the current price. Call activity is sparse and skewed toward out-of-the-money strikes further away, indicating a lack of immediate bullish conviction despite some speculative interest in higher targets for later dates.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.31372547 |
| Address1 | Paul-Ehrlich-Strasse 15-19 |
| All Time High | 18.42 |
| All Time Low | 0.005 |
| Ask | 8.84 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 957,140 |
| Average Daily Volume3 Month | 654,839 |
| Average Volume | 654,839 |
| Average Volume10Days | 957,140 |
| Beta | 1.364 |
| Bid | 5.17 |
| Bid Size | 2 |
| Book Value | 3.2630963 |
| City | Tübingen |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Germany |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 7.17 |
| Current Ratio | 7.536 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 7.2 |
| Day Low | 6.9525 |
| Debt To Equity | 3.655 |
| Display Name | Immatics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,787,056,200 |
| Earnings Timestamp End | 1,794,918,600 |
| Earnings Timestamp Start | 1,794,918,600 |
| Ebitda | -218,028,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.651 |
| Enterprise To Revenue | 13.862 |
| Enterprise Value | 578,085,824 |
| Eps Current Year | -2.05738 |
| Eps Forward | -2.02562 |
| Eps Trailing Twelve Months | -1.87 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fax | 49 7071 5397 900 |
| Fifty Day Average | 8.7688 |
| Fifty Day Average Change | -1.5987997 |
| Fifty Day Average Change Percent | -0.18232822 |
| Fifty Two Week Change Percent | -31.372547 |
| Fifty Two Week High | 12.41 |
| Fifty Two Week High Change | -5.24 |
| Fifty Two Week High Change Percent | -0.4222401 |
| Fifty Two Week Low | 6.73 |
| Fifty Two Week Low Change | 0.44000006 |
| Fifty Two Week Low Change Percent | 0.06537891 |
| Fifty Two Week Range | 6.73 - 12.41 |
| Financial Currency | EUR |
| First Trade Date Milliseconds | 1,544,625,000,000 |
| Float Shares | 70,119,224 |
| Forward Eps | -2.02562 |
| Forward P E | -3.539657 |
| Free Cashflow | -126,542,624 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 704 |
| Fullday Change | 0.17000008 |
| Fullday Change Percent | 2.4285724 |
| Fullday Price | 7.17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -176,711,008 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.15785 |
| Held Percent Institutions | 0.66758 |
| Implied Shares Outstanding | 152,225,077 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is in Phase 2 trial; IMA203CD8, a cell therapy product that is in Phase 1 clinical trial; IMA204 that targets tumor stroma, which is in Phase 1 clinical trial; and Anzu-cel in combination with Moderna's PRAME cell therapy enhancer (mRNA-4203), which is in Phase 1 clinical trial. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. |
| Long Name | Immatics N.V. |
| Market | us_market |
| Market Cap | 1,091,453,824 |
| Market State | REGULAR |
| Max Age | 86,400 |
| Message Board Id | finmb_8986547 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -206,548,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,309,896,787 |
| Number Of Analyst Opinions | 7 |
| Open | 7.05 |
| Operating Cashflow | -205,868,992 |
| Operating Margins | -7.34952 |
| Payout Ratio | 0.0 |
| Phone | 49 7071 5397 0 |
| Previous Close | 7.0 |
| Price Eps Current Year | -3.485015 |
| Price Hint | 2 |
| Price To Book | 2.1972995 |
| Price To Sales Trailing12 Months | 26.171442 |
| Profit Margins | 0.0 |
| Quick Ratio | 7.024 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.17000008 |
| Regular Market Change Percent | 2.4285724 |
| Regular Market Day High | 7.2 |
| Regular Market Day Low | 6.9525 |
| Regular Market Day Range | 6.9525 - 7.2 |
| Regular Market Open | 7.05 |
| Regular Market Previous Close | 7.0 |
| Regular Market Price | 7.17 |
| Regular Market Time | 1,792,094,203 |
| Regular Market Volume | 1,040,745 |
| Return On Assets | -0.2692 |
| Return On Equity | -0.47801 |
| Revenue Growth | 0.93 |
| Revenue Per Share | 0.322 |
| Sand P52 Week Change | 0.16440773 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 152,225,077 |
| Shares Percent Shares Out | 0.0242 |
| Shares Short | 3,690,633 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 4,853,483 |
| Short Name | Immatics N.V. |
| Short Percent Of Float | 0.0336 |
| Short Ratio | 5.07 |
| Source Interval | 15 |
| Symbol | IMTX |
| Target High Price | 25.0 |
| Target Low Price | 11.8 |
| Target Mean Price | 17.25714 |
| Target Median Price | 17.0 |
| Total Cash | 393,350,016 |
| Total Cash Per Share | 2.878 |
| Total Debt | 14,606,000 |
| Total Revenue | 41,704,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.87 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.739125 |
| Two Hundred Day Average Change | -2.5691252 |
| Two Hundred Day Average Change Percent | -0.26379424 |
| Type Disp | Equity |
| Volume | 1,040,745 |
| Website | https://www.immatics.com |
| Zip | 72,076 |